Pharmacyclics
David Ipe is a seasoned professional in the field of biostatistics with extensive experience in various leadership roles. Currently serving as Director of Biostatistics at AbbVie since September 2021, David previously held the position of Associate Director of Biostatistics at Pharmacyclics, an AbbVie Company, starting in January 2015. Prior to these roles, David accumulated significant experience at Genentech and Roche, where positions included Project Statistician and Statistical Scientist, beginning as early as 1985. David's academic background includes studies at Purdue University from 1982 to 1984.
This person is not in any teams
This person is not in any offices
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.